To do an evaluation between surfactants with additional excipients regarding their presence in commercially available antibody formulations is not possible, mainly because additional excipients might have been used to fulfill a different part in the formulation. products shelf-life, and compatible with other formulation parts and the primary packaging are highly sought after. Opn5 The aim of this paper is definitely to review potential alternate excipients from different family members, including surfactants, carbohydrate- and amino acid-based excipients, synthetic amphiphilic polymers, and ionic liquids that enable protein stabilization. For Lumefantrine each category, important characteristics such as the ability to stabilize proteins against thermal and mechanical tensions, current knowledge related to the security profile for parenteral administration, potential relationships with additional formulation parts, and primary packaging are debated. Based on the offered information and the detailed discussion thereof, this paper may pave the way for the recognition or development of efficient excipients for biotherapeutic protein stabilization. Keywords: polysorbate alternatives, excipient, surfactant, protein stabilization, protein biotherapeutic formulations 1. Intro The term biotherapeutics encompasses a wide range of biological products used with the perfect objective of treating numerous human diseases. Unlike small molecular drugs, however, the production of biotherapeutics, at least in part, requires the use of Lumefantrine a living sponsor, capable of generating molecules with higher multidimensional difficulty with secondary, tertiary, and even quaternary conformations [1]. Biotherapeutics comprise a broad range of biologically-derived therapeutics [2]. Among these, protein therapeutics are the most extensively developed group and form a major part of the FDA-approved biotherapeutics. Protein therapeutics consist of diverse subclasses such as antibodies (Ab), Fc-fusion proteins, blood factors and anticoagulants, enzymes, growth factors, protein hormones, cytokines, thrombolytics, scaffold proteins, etc. These are often used to replace deficient or irregular proteins, promote or inhibit numerous cellular pathways, exert a new and non-existing function, interfere Lumefantrine with a molecule of interest, or deliver numerous cargos to specific targets [3]. While the nature and the purpose of protein therapeutics is quite diverse, monoclonal Abdominal muscles (mAb) remain probably the most common subcategory in terms of clinical application. In general, the development of protein therapeutics is definitely a complex multiple step process, during which keeping the protein integrity from Lumefantrine your purification up to the administration of the final product to the patient is definitely fraught with several and diverse difficulties. Given their complex higher order conformational structures as well as the presence of numerous functional groups, protein biotherapeutics are vulnerable not only to chemical degradation, but also to physical-induced conformational changes. The chemical instabilities are related to the breakage and/or formation of covalent bonds in the proteins first-order structure, generated by intramolecular modifications such as non-reducible cross-linking [4,5], deamidation [4,6,7,8,9], formation of fundamental or acidic varieties [10,11], glycation (Maillard reaction) [12], isomerization [6,13] oxidation [4,11], fragmentation [10,14], C-terminal clipping [15], reduction [16], hydrolysis [17], and racemization [18]. Physical-induced conformational changes, on the other hand, are often in the form of denaturation [19,20], aggregation [21,22,23,24,25], surface adsorption [26], precipitation and unfolding [27], often impacting the secondary or tertiary constructions of the proteins [28]. The challenges associated with keeping the features and integrity of the protein drugs become more pronounced in the case of mAb-based therapeutics, as they often require higher dose concentrations (usually 50C200 mg/mL). The development of such high concentration liquid formulations (HCLF) comes along with additional challenges in terms of protein solubility and hydration, colloidal and conformational stability, and remedy properties [29,30,31,32], which are directly related to the formation of mAb particles [33,34]. With increasing protein concentration of the biotherapeutic, viscosity and opalescence of the formulation also increases, and liquidCliquid phase separation phenomenon becomes more likely to occur [35]. While the liquidCliquid phase separation does not effect the native protein structure per se, it promotes reversible or irreversible protein particle formation, which can result Lumefantrine in a reduction of the restorative effectiveness and result in immune reactions upon administration [36]. Furthermore, exposure to numerous interfaces (airCliquid, solidCliquid, and liquidCliquid) during different phases of developing, including freezeCthawing, pumping, sterile filtration, lyophilization, and fill and finish processes, as well as numerous post-production phases such as storage in the primary packaging and transportation, can promote conformational changes leading to protein denaturation [37,38,39,40,41,42]. When inadequately formulated, proteins are adsorbed to such interfaces by virtue of their amphiphilic properties, and thus undergo conformational changes to reduce the interfacial pressure, or else create viscoelastic interfacial protein gels. While the former can act as a nucleating point for further protein particle formation, the second option can facilitate agitation-mediated formation of protein particles [43,44]. The formation of such protein particles can in turn affect the quality of the final product and lead to undesirable consequences such as irreversible loss of activity, boost of the visible or sub-visible particle levels beyond the permitted threshold, and potential immunogenicity [45,46,47,48]. Hence, conserving the integrity of the protein drug from all potential sources of stress detailed above isn’t just relevant but of vital importance. While factors such as harsh temps and intense acidity or alkalinity can be more easily avoided, stress-induced physicochemical protein.